Tianjin Pacific Pharmaceutical Co., Ltd.

The main purpose of the study is to use the isosorbide dinitrate tablets (specification: 5 mg) developed by Tianjin Pacific Pharmaceutical Co., Ltd. as the test preparation and the isosorbide dinitrate tablets (trade name: ISORDIL®, specification: 5 mg) certified by Bausch Health US, LLC as the reference preparation, to compare the relative bioavailability in healthy humans and investigate the human bioequivalence of the two preparations. Secondary purpose of the study: to observe the safety of the test preparation and reference preparation of isosorbide dinitrate tablets (trade name: ISORDIL®) in healthy subjects.

The main purpose of the study is to use isosorbide dinitrate tablets (specification: 5 mg) developed by Tianjin Pacific Pharmaceutical Co., Ltd. as the test preparation (T) and isosorbide dinitrate tablets (trade name: ISORDIL®, specification: 5 mg) produced by Bausch Health US, LLC as the reference preparation (R). The pharmacokinetic characteristics of healthy subjects after a single oral administration of the test preparation or the reference preparation under high-fat meal conditions are compared, the main pharmacokinetic parameters are calculated, and the bioequivalence of the two preparations is preliminarily evaluated to provide a reference for the design of the formal trial. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation of isosorbide dinitrate tablets in healthy subjects.